Despite its relatively lower expression in TNBC compared to HER2-psitive and luminal breast cancers, accumulating evidence suggests that HER3 remains functionally relevant in TNBC tumorigenesis, especially in the presence of its ligand, HRG-β1 [22, 23, 44–46]. The gene discussed is ERBB2; the disease is breast carcinoma.